Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19767773
Hassan S, et al. (2009) Heat shock protein 27 mediates repression of androgen receptor function by protein kinase D1 in prostate cancer cells. Oncogene 28, 4386-96 19767773
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S82-p - HSP27 (human)
Modsite: RALsRQLssGVsEIr SwissProt Entrez-Gene
Orthologous residues
HSP27 (human): S82‑p, HSP27 (mouse): S86‑p, HSP27 (rat): S86‑p, HSP27 (pig): S84‑p, HSP27 (hamster): S90‑p, HSP27 (chicken): S80‑p, HSP27 (dog): S86‑p, HSP27 (cow): S78‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  C4-2 (prostate cell), LNCaP (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bombesin increase
SB203580 bombesin inhibit treatment-induced increase
bombesin PRKD1 (human) increase PKD1 shRNA abolishes increase
neurotensin increase
SB203580 neurotensin inhibit treatment-induced increase
neurotensin PRKD1 (human) increase PKD1 shRNA abolishes increase
bryostatin_1 increase
SB203580 bryostatin_1 inhibit treatment-induced increase
Go_6976 bryostatin_1 inhibit treatment-induced increase
bryostatin_1 PRKD1 (human) increase PKD1 shRNA abolishes increase
SB203580 no change compared to control

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  C4-2 (prostate cell), LNCaP (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bombesin increase
SB203580 bombesin inhibit treatment-induced increase
bombesin PRKD1 (human) increase PKD1 shRNA abolishes increase
neurotensin increase
SB203580 neurotensin inhibit treatment-induced increase
neurotensin PRKD1 (human) increase PKD1 shRNA abolishes increase
bryostatin_1 increase
SB203580 bryostatin_1 inhibit treatment-induced increase
Go_6976 bryostatin_1 inhibit treatment-induced increase
bryostatin_1 PRKD1 (human) increase PKD1 shRNA abolishes increase
SB203580 no change compared to control

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  C4-2 (prostate cell), LNCaP (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bombesin increase
SB203580 bombesin inhibit treatment-induced increase
bombesin PRKD1 (human) increase PKD1 shRNA abolishes increase
neurotensin increase
SB203580 neurotensin inhibit treatment-induced increase
neurotensin PRKD1 (human) increase PKD1 shRNA abolishes increase
bryostatin_1 increase
SB203580 bryostatin_1 inhibit treatment-induced increase
Go_6976 bryostatin_1 inhibit treatment-induced increase
bryostatin_1 PRKD1 (human) increase PKD1 shRNA abolishes increase
SB203580 no change compared to control

S910-p - PRKD1 (human)
Modsite: KALGERVsIL_____ SwissProt Entrez-Gene
Orthologous residues
PRKD1 (human): S910‑p, PRKD1 (mouse): S916‑p, PRKD1 (rat): S916‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  C4-2 (prostate cell), LNCaP (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bombesin increase
SB203580 bombesin no effect upon treatment-induced increase
neurotensin increase
SB203580 neurotensin no effect upon treatment-induced increase
bryostatin_1 increase
SB203580 bryostatin_1 no effect upon treatment-induced increase
Go_6976 bryostatin_1 inhibit treatment-induced increase
Go_6976 no change compared to control
SB203580 no change compared to control